argenex (NASDAQ:ARGX) Stock Rating Upgraded by Deutsche Bank Aktiengesellschaft

argenex (NASDAQ:ARGX - Get Free Report) was upgraded by investment analysts at Deutsche Bank Aktiengesellschaft from a "hold" rating to a "buy" rating in a report issued on Tuesday, MarketBeat.com reports.

Several other research analysts also recently commented on ARGX. Citigroup reissued a "buy" rating on shares of argenex in a research note on Wednesday, May 21st. JMP Securities set a $699.00 target price on argenex in a research note on Wednesday, May 14th. Oppenheimer boosted their target price on argenex from $704.00 to $708.00 and gave the stock an "outperform" rating in a research note on Friday, May 9th. Baird R W raised argenex from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, May 13th. Finally, Guggenheim lowered their target price on argenex from $1,100.00 to $1,065.00 and set a "buy" rating for the company in a research note on Friday, May 9th. Nineteen research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $728.06.

argenex Price Performance

ARGX stock traded up $5.64 during midday trading on Tuesday, reaching $544.28. 335,397 shares of the company were exchanged, compared to its average volume of 331,903. The business has a 50-day moving average price of $572.66 and a two-hundred day moving average price of $603.28. argenex has a one year low of $442.75 and a one year high of $678.21. The firm has a market capitalization of $33.23 billion, a price-to-earnings ratio of 33.58, a price-to-earnings-growth ratio of 0.99 and a beta of 0.37.

argenex (NASDAQ:ARGX - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $2.58 EPS for the quarter, topping analysts' consensus estimates of $2.32 by $0.26. argenex had a net margin of 40.20% and a return on equity of 16.15%. The firm had revenue of $1.35 billion during the quarter, compared to analysts' expectations of $748.34 million. As a group, analysts anticipate that argenex will post 3.13 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. GeoWealth Management LLC lifted its holdings in shares of argenex by 56.3% during the fourth quarter. GeoWealth Management LLC now owns 50 shares of the company's stock valued at $31,000 after purchasing an additional 18 shares in the last quarter. Rakuten Securities Inc. increased its position in argenex by 56.4% in the first quarter. Rakuten Securities Inc. now owns 61 shares of the company's stock worth $36,000 after buying an additional 22 shares in the last quarter. WPG Advisers LLC purchased a new stake in argenex in the first quarter worth about $37,000. FIL Ltd purchased a new stake in argenex in the fourth quarter worth about $38,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in argenex in the fourth quarter worth about $38,000. 60.32% of the stock is owned by institutional investors.

About argenex

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.